NextPoint Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch NextPoint Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies (NCT07563829) | NextPoint Therapeutics, Inc. | 2026-04-01 |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 (NCT06240728) | NextPoint Therapeutics, Inc. | 2024-01-22 |
| A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 (NCT05958199) | NextPoint Therapeutics, Inc. | 2023-07-21 |
Track NextPoint Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.